Erythropoietin (Epo), a glycoprotein hormone that is the principal regulator of erythropoiesis,
is known to act also on nonhematopoietic cell types. Epo receptors have been reported on …

Erythropoietin (Epo), the major regulator of erythropoiesis, and its cognate receptor (EpoR)
are also expressed in nonerythroid tissues, including tumors. Clinical studies have …

Erythropoietin (EPO) is a hematopoietic growth hormone that regulates survival,
proliferation, and differentiation of erythroid progenitor cells. A reduction in tissue …

Erythropoietin (Epo) is a cytokine that binds and activates an Epo receptor (EpoR)
expressed on the surface of erythroid progenitor cells to promote erythropoiesis. While early …

Erythropoietin (EPO), a humoral regulator of erythropoiesis and replacement therapy for
selected red blood cell disorders in EPO-deficient patients, has been implicated in a wide …

Erythropoiesis-stimulating agents (ESAs) increase red blood cell (RBC) production in bone
marrow by activating the erythropoietin receptor (EpoR) on erythrocytic-progenitor cells …

Background Several clinical studies have shown that recombinant human erythropoietin
(rHuEpo) can ameliorate the anemia associated with hematologic malignancies and solid …

Erythropoiesis is maintained by the hormone erythropoietin (Epo) binding to its cognate
receptor (EpoR) on erythroid progenitor cells. The Epo-EpoR interaction initiates a signal …

Erythropoietin (EPO) regulates mammalian erythropoiesis by binding to its transmembrane
receptor EPOR. Recent studies demonstrated functional EPOR expression in human cancer …

Recombinant human erythropoietin has become an essential part of the management of
anemic patients with end-stage renal disease. It is also used to treat the anemia associated …